Welcome to our dedicated page for Glaukos SEC filings (Ticker: GKOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Glaukos Corporation (GKOS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret the information. Glaukos is an ophthalmic pharmaceutical and medical technology company focused on therapies for glaucoma, corneal disorders, and retinal diseases, and its filings provide detailed insight into this business.
Through periodic reports such as Forms 10-Q and 10-K, investors can review Glaukos’ net sales, segment performance in glaucoma and corneal health, gross margins, operating expenses, and net income or loss. These filings also describe risk factors relevant to its ophthalmic device and pharmaceutical portfolio, including regulatory requirements, clinical trial processes, reimbursement dynamics, manufacturing considerations, and intellectual property matters referenced in the company’s public communications.
Current reports on Form 8-K capture material events such as quarterly and annual financial results, preliminary net sales updates, and investor presentations. For example, Glaukos has filed 8-Ks to furnish press releases on second and third quarter financial results, preliminary unaudited net sales for a fiscal year, and investor presentation materials. These documents often include or reference revenue guidance ranges and explanations of non-GAAP financial measures and constant currency net sales metrics.
On Stock Titan, AI-generated summaries help explain the key points of lengthy filings, highlighting items such as revenue trends, segment details, and notable risk disclosures without replacing the full text. Real-time updates from EDGAR ensure new Glaukos filings appear promptly, while dedicated sections make it straightforward to locate quarterly reports, annual reports, and current reports tied to material announcements.
For users analyzing GKOS, this page offers a structured view of Glaukos’ SEC reporting history alongside AI insights that clarify complex financial and regulatory information related to its ophthalmic pharmaceutical and medical technology activities.
Glaukos Corporation’s Chairman and CEO Thomas William Burns reported planned option exercises and share sales under a Rule 10b5-1 trading plan. On January 8 and 16, 2026, he exercised stock options with a strike price of $16.49 to acquire 88,055 and 186,945 shares of common stock, respectively, then sold the same numbers of shares at a price of $115 per share. Following these transactions, he reported 153,775 shares of common stock beneficially owned directly, which the filing notes includes 89,621 restricted stock units that have not yet vested or been delivered. He also reported additional indirect holdings in several Burns family-related trusts.
Glaukos Corporation insider Thomas Burns has filed a notice of proposed stock sales under Rule 144. The filing covers 186,945 shares of common stock to be sold through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $21,498,675.00 and 57,434,740 shares of common stock outstanding.
The shares to be sold were acquired on January 16, 2026 through the cash exercise of a stock option that was originally granted on March 10, 2016, with 186,945 shares acquired and paid in cash on that date. Over the prior three months, Burns sold 88,055 shares of Glaukos common stock on January 8, 2026 for gross proceeds of $10,126,325.00.
Glaukos Corporation filed a current report describing new financial communications to the market. The company issued a press release with its preliminary, unaudited net sales results for the fourth quarter and full fiscal year ended December 31, 2025, and furnished this release as Exhibit 99.1. Glaukos also prepared an investor presentation, furnished as Exhibit 99.2, which it intends to use in meetings with investors and other stakeholders and make available on its investor relations website. The company notes that the information in these exhibits is being furnished rather than filed under securities laws, which affects how it is treated for legal liability and incorporation into other regulatory documents.
The issuer of GKOS common stock has filed a notice of proposed sale under Rule 144 for 88,055 shares of common stock through Fidelity Brokerage Services LLC. The shares have an stated aggregate market value of 10,126,325.00, based on the information in the filing.
The filing notes that the shares were acquired on 01/08/2026 by exercising a stock option that was originally granted on 03/10/2016, with the purchase price paid in cash. The notice lists 57,434,740 shares of the issuer’s common stock as outstanding and indicates an approximate sale date of 01/08/2026 on the NYSE.
Glaukos Corporation director David F. Hoffmeister reported receiving a grant of 753 restricted stock units of Glaukos common stock on January 2, 2026. The filing states this equity award was made under the company’s Director Compensation Policy, will vest in full on the one-year anniversary of the grant date, and will be settled in an equivalent number of Glaukos common shares.
After this grant, Hoffmeister is shown as beneficially owning 32,671 shares of common stock directly, which the footnotes explain include 2,861 restricted stock units that have not yet vested or been delivered, along with vested units whose delivery has been deferred. He is also reported as indirectly beneficially owning 38,176 shares of Glaukos common stock through Sentinel Point Partners, Inc.
Glaukos Corporation director Leana Wen received a grant of 623 restricted stock units on January 2, 2026 under the company’s director compensation policy. These restricted stock units will vest in full on the one-year anniversary of the grant date and will be settled in an equivalent number of Glaukos common shares.
After this grant, Wen beneficially owns 21,439 shares of common stock, which includes 2,731 restricted stock units that have not yet vested or been delivered, as well as restricted stock units that have vested but whose delivery has been deferred.
Glaukos Corporation director Aimee S. Weisner reported receiving a grant of 623 shares of common stock on January 2, 2026. According to the disclosure, this represents a grant of restricted stock units under Glaukos’ Director Compensation Policy, which will vest in full on the one-year anniversary of the grant date and be settled in an equal number of common shares.
After this grant, Weisner beneficially owns 19,786 shares of common stock directly, which includes 2,731 restricted stock units that have not yet vested or been delivered, as well as vested units for which delivery has been deferred. She also reports indirect holdings of 28,525 shares through the Saeman-Weisner Family Trust and 2,000 shares through the Weisner Saeman Family Irrevocable Trust.
Glaukos Corporation director Denice Torres reported receiving a new equity grant. On January 2, 2026, she was awarded 623 shares of Glaukos common stock at a price of $0 per share, reflecting a grant of restricted stock units under the company’s Director Compensation Policy. These units will vest in full on the one-year anniversary of the grant date and will be settled in the same number of common shares.
After this grant, Torres beneficially owns 22,334 shares of Glaukos common stock, including 2,731 restricted stock units that have not yet vested or been delivered. The filing classifies her holdings as directly owned and confirms her role as a director, with no indication that she is a 10% owner or an officer of the company.
Glaukos Corp director Gilbert H. Kliman reported an equity grant of 623 restricted stock units on January 2, 2026. The award was made under the company’s Director Compensation Policy at a grant price of $0 per share. These units will vest in full on the one-year anniversary of the grant date and will be settled in the same number of Glaukos common shares. Following this grant, Kliman beneficially owns 35,528 shares of common stock, which includes 2,731 restricted stock units that have not yet vested or been delivered, as well as vested units for which delivery has been deferred.
Glaukos Corporation director Mark J. Foley reported an equity award in the form of restricted stock units. On 01/02/2026, he received 1,168 restricted stock units of Glaukos common stock at a stated price of $0 per share under the company’s Director Compensation Policy. These units will vest in full on the one-year anniversary of the grant date and are then payable in an equivalent number of Glaukos common shares.
Following this grant, Foley beneficially owns 58,389 shares of common stock, which the disclosure notes includes 3,276 restricted stock units that have not yet vested or been delivered.